Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non Operating Income (2017 - 2026)

Crinetics Pharmaceuticals has reported Non Operating Income over the past 9 years, most recently at -$41.0 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 18688.07% year-over-year to -$41.0 million; the TTM value through Dec 2025 reached -$27.7 million, down 437.33%, while the annual FY2025 figure was -$357000.0, 31.21% up from the prior year.
  • Non Operating Income for Q4 2025 was -$41.0 million at Crinetics Pharmaceuticals, down from -$49000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $13.5 million in Q2 2025 and troughed at -$41.0 million in Q4 2025.
  • A 5-year average of -$816200.0 and a median of -$6000.0 in 2021 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: soared 8575.86% in 2023 and later crashed 18688.07% in 2025.
  • Year by year, Non Operating Income stood at $171000.0 in 2021, then crashed by 1475.44% to -$2.4 million in 2022, then surged by 101.7% to $40000.0 in 2023, then plummeted by 645.0% to -$218000.0 in 2024, then crashed by 18688.07% to -$41.0 million in 2025.
  • Business Quant data shows Non Operating Income for CRNX at -$41.0 million in Q4 2025, -$49000.0 in Q3 2025, and $13.5 million in Q2 2025.